Novartis Oral Multiple Sclerosis Development Compound Gilenia (FTY720)Granted US Priority Review Status
Feb 22, 2010
(RTTNews) – Novartis AG (NVS:News ) said Gilenia has been granted priority review status by the US Food and Drug Administration, which accepted the regulatory submission made in December 2009 for this medicine. Once-daily Gilenia (0.5 mg) has the potential to become the first approved oral therapy for the treatment of multiple sclerosis.
The FDA grants priority reviews for investigational medicines that could offer significant advances beyond current treatments or where no adequate therapy exists. As a result of this designation, the standard 10-month FDA review period will be reduced to six months.
by RTT Staff Writer
For comments and feedback: to th is article, see original posting to comment to their editor.
Or leave a comment on this blog posting
######################
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the “Stu’s Views and MS Related News”, weekly M.S. e-newsletter, then please take 20 seconds to register at: https://www.msviewsandnews.org. – Thank you
######################
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews